Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in IDH-Mutant Advanced Intrahepatic Cholangiocarcinoma
NCT02428855Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2015
- Primary completion
- Feb 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA), gallbladder cancer, sponsored by Massachusetts General Hospital. Started Apr 2015; status: completed.
02
Drugs
dasatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancer
Beyond the preview
Go deeper on NCT02428855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02428855.